WO2018086550A1 - 一种生物学活性组分结肠靶向组合物及其应用 - Google Patents

一种生物学活性组分结肠靶向组合物及其应用 Download PDF

Info

Publication number
WO2018086550A1
WO2018086550A1 PCT/CN2017/110074 CN2017110074W WO2018086550A1 WO 2018086550 A1 WO2018086550 A1 WO 2018086550A1 CN 2017110074 W CN2017110074 W CN 2017110074W WO 2018086550 A1 WO2018086550 A1 WO 2018086550A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
active component
biologically active
colon
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/110074
Other languages
English (en)
French (fr)
Inventor
张钧寿
孙超男
张昊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Healsoul Life Science And Technology Co Ltd
Original Assignee
Nanjing Healsoul Life Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Healsoul Life Science And Technology Co Ltd filed Critical Nanjing Healsoul Life Science And Technology Co Ltd
Priority to US16/349,093 priority Critical patent/US11337926B2/en
Priority to RU2019116519A priority patent/RU2744452C2/ru
Priority to EP17869993.0A priority patent/EP3539538B1/en
Priority to JP2019546961A priority patent/JP6989154B2/ja
Publication of WO2018086550A1 publication Critical patent/WO2018086550A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • Biologically active components are a large class of physiologically active components that, through the acquisition of appropriate biologically active components, can play an important role in nutritional improvement, disease prevention and treatment, and health care.
  • most of the biologically active components often have the following problems when administered orally: 1) the upper digestive tract environment (such as gastric acid, digestive enzymes, etc.) has considerable destructive activity on the activity of most biologically active components, As for the active components, the active components cannot fully exert the corresponding effects; 2) the biologically active components are abundantly present in the stomach and small intestine after oral administration, and are not advantageously absorbed and utilized by the human body, thereby easily causing corresponding harm to the body; 3) harsh Production and processing conditions (such as temperature, humidity, introduction of some solvents, etc.) have a destructive effect on the activity of the components.
  • colon-targeted drug delivery systems are mainly divided into time-delay drug delivery systems, pH-dependent drug delivery systems, enzyme-activated drug delivery systems, pressure-dependent drug delivery systems, and prodrugs.
  • Type drug delivery system The time-delayed drug delivery system uses the substance to pass through the stomach and the small intestine to reach the colon in turn, which requires a time lag of 5 to 6 hours, so that the drug is not released in the stomach and small intestine, and is released only after reaching the colon; the pH-dependent drug delivery system is utilized.
  • the bioavailability of the fractions is better at exerting its in vivo activity, thereby solving the above problems in the prior art.
  • the present invention provides a bioactive component colon targeting composition based on hypromellose (HPMC), comprising: hypromellose, a biologically active component, and an excipient, wherein The hypromellose content is from 10 to 99% by weight, the biologically active component is from 1 to 60% by weight, and the excipient is from 0 to 80% by weight; further preferably, The weight ratio of the hypromellose is 40 to 90%, the weight percentage of the biologically active component is 10 to 40%, and the weight percentage of the auxiliary material is 0 to 50%; Wherein the hypromellose has a viscosity of >1000 mPa.s.
  • HPMC hypromellose
  • the hypromellose has a viscosity of from 15,000 mPa.s to 200,000 mPa.s.
  • the biologically active component is a microorganism; more preferably, the microorganism is a probiotic,
  • the probiotic includes one or more of Bifidobacterium, Lactobacillus or Gram-positive cocci which are allowed to be used in foods, health care products and pharmaceuticals; preferably, the Bifidobacterium is Bifidobacterium lactis, infant One or more of Bifidobacterium, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium adolescentis; the Lactobacillus is Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispum, Lactobacillus delbrueckii subsp.
  • the excipient comprises nutrients which are beneficial to the survival stability of the biologically active component
  • the nutrient may be a prebiotic (such as oligofructose, galactooligosaccharide, xylooligosaccharide, oligofructose, soybean) Oligosaccharides, pectins, inulin and cranberry powder, etc.), vitamins and/or sugar alcohols.
  • a biologically active component colon targeting composition of the invention for the preparation of a biologically active component colon targeted formulation.
  • Figure 2 Dissolution profiles of tablets prepared with hypromellose of different viscosities after sequential application of artificial gastric juice for 2 h, artificial intestinal fluid for 3 h, and artificial colonic fluid for 18 h.
  • the probiotic powder used in the present invention includes: Bifidobacterium lactis BLa80, Bifidobacterium longum BL21, Lactobacillus acidophilus LA85 and Bifidobacterium bifidum BBi32, which are derived from Jiangsu Zishi Weikang Biotechnology Co., Ltd.; Lactobacillus licheniformis R11, Bifidobacterium longum R175 and Bifidobacterium lactis lafti B84, which are from the French company LALLEMAND.
  • Hypromellose K4M, K15M, K100M used Originated from Anhui Shanhe Accessories Co., Ltd., the hypromellose K100LV and K200M used are from Dow Chemical.
  • the mixture powder is directly dry-pressed into tablets, the tablet weight is 300 mg, the tablet diameter is 10 mm, the viable count of Bifidobacterium lactis is 2.5*10 10 cfu/g, and the viable count of Bifidobacterium longum is 3.75* 10 10 cfu/g.
  • Si Liankang tablets (Bifidobacterium quadruple live bacteria tablets, 500mg/tablet, wherein Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis are not less than 0.5*10 6 cfu/g, respectively, waxy The Bacillus is not less than 0.5*10 5 cfu/g, and the auxiliary material is starch and milk powder.)
  • the tablets prepared in the above examples are dissolved and tested for viable count.
  • the culture medium is placed in a water bath at 52 ° C for use, and the culture dish is placed at room temperature for cooling.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Animal Husbandry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physiology (AREA)

Abstract

一种生物学活性组分结肠靶向组合物及其制剂和制备方法，该生物学活性组分结肠靶向组合物包括：重量百分含量为10-99%的羟丙甲纤维素、重量百分含量为1-60%的生物学活性组分和重量百分含量为0-80%的辅料，其中羟丙甲纤维素的粘度>1000mPa.s。该生物学活性组分结肠靶向组合物具有改进的结肠靶向效果，提高了生物学活性组分的生物利用度和体内活性。

Description

一种生物学活性组分结肠靶向组合物及其应用 技术领域
本发明属于食品、保健品与药品技术领域，具体涉及一种生物学活性组分结肠靶向组合物、其制剂和它们的制备方法。
背景技术
生物学活性组分是一大类具有生理活性的组分，通过获取适当的生物学活性组分，可对营养的改善、疾病的预防和治疗以及保健起到重要作用。然而，大多数的生物学活性组分经口服时往往存在以下问题：1)上消化道环境(如胃酸、消化酶等)对大部分生物学活性组分的活性具有相当大的破坏力，以至于这些活性组分不能充分发挥相应作用；2)生物学活性组分经口服后大量存在于胃及小肠，无法被人体有利地吸收和利用，从而容易对机体产生相应的危害；3)苛刻的生产加工条件(如温度、湿度、一些溶剂的引入等)对组分活性有破坏作用。
基于上述问题，结肠靶向传递系统通过使用适当的方法，能避免有效物质在胃、十二指肠、空肠和回肠释放，直接运送到患者的结肠部位释放，可提高有效物质在结肠部位的局部浓度，便于充分吸收、充分发挥治疗和保健作用，避免在胃及小肠的释放，降低不良反应，提高易被胃酸破坏或易被胃蛋白酶、胰酶代谢的有效物质的生物利用度，从而大大弥补了上述不足。
结合现代药物制剂技术来设计剂型，结肠靶向给药传递系统主要分为时滞型释药系统、pH依赖型释药系统、酶触发型释药系统、压力依赖型释药系统及前体药物型释药系统。时滞型释药系统利用物质口服依次经过胃、小肠到达结肠需要5～6h的时滞特点而使药物在胃、小肠不释放，而到达结肠后才开始释放；pH依赖型释药系统是利用胃肠道pH条件的不同，通过选择包衣方法，以达到结肠释放目的，包衣制备过程较复杂，需使用溶剂且溶剂需要在一定的温度下挥发干净，该方法很可能导致生物学活性组分的活力显著下降。酶触发型释药系统、压力依赖型释药系统以及前体药物型释药系统目前虽受重视，但三者的非常规性的限制、内在复杂性，甚至是需要专业化的装置和复杂的处理步骤不仅增加了研发过程的复杂性，并且大大降低了产品大规模生产的可能性。
生物学活性组分，特别是有益微生物的活性难以耐受相关制剂制备过程中稍高温度或湿度、溶剂或者其他物质的影响，因此其结肠靶向传递系统的研究和开发受到极大的限制，往往越是复杂的制备工艺对其活性的破坏越大，因而 迄今为止尚未见到结肠靶向的益生菌相关产品面市。
现有的益生菌制剂技术能使得益生菌绕过胃而在小肠中释放，但即便是这样，若益生菌在小肠中过多地聚集，也会出现严重的肠道菌群失调等安全性问题(CN200910229403.2)。现有的益生菌制剂技术虽能将益生菌递送到胃肠道的远端区段(包括回肠)，但却并非能直接定位递送到结肠，因此益生菌的利用率并不能达到最佳(US2016022592)。现有的益生菌制剂技术还存在所用辅料的安全性问题(ALBERTINI B,VITALI B,PASSERINI N,et al.Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis[J].European Journal of Pharmaceutical Sciences,2010,40(4):359-366.)。现有的益生菌制剂技术无法避免制备过程中所用溶剂以及制备时升高的温度、湿度等对益生菌活性的影响(KLEMMER K J,KORBER D R,NICHOLAS H,et al.Pea proteinbased capsules for probiotic and prebiotic delivery[J].International Journal of Food Science and Technology,2011,46(11):2248-2256.)。现有的益生菌制剂技术为了满足有效口服剂型的条件，往往所需用的辅料体积较大，载活菌数较低。现有的益生菌制剂技术制备工艺复杂，难以工业化生产(CALINESCU C,MATEESCU M A.Carboxymethyl high amylase starch:chitosan self-stabilized matrix for probiotic colon delivery[J].European Journal of Pharmaceutics and Biopharmaceutics,2008,70(2):582-589.)。
发明内容
本发明的目的是提供一种生物学活性组分的结肠靶向组合物及含有该组合物的制剂，它们能够经过胃和小肠、大部分在到达结肠部位后才释放，从而提高生物学活性组分的生物利用度，更好地发挥其体内活性，从而解决现有技术存在的上述问题。
本发明是通过以下方式实现的：
一方面，本发明提供了一种基于羟丙甲纤维素(HPMC)的生物学活性组分结肠靶向组合物，包括：羟丙甲纤维素、生物学活性组分和辅料，其中，所述羟丙甲纤维素的重量百分含量为10～99％，所述生物学活性组分的重量百分含量为1～60％，辅料的重量百分含量为0～80％；进一步优选地，所述羟丙甲纤维素的重量百分含量为40～90％，所述生物学活性组分的重量百分含量为10～40％，所述辅料的重量百分含量为0～50％；其中，所述羟丙甲纤维素的粘度>1000mPa.s。
优选地，所述羟丙甲纤维素的粘度为15000mPa.s-200000mPa.s。
优选地，所述生物学活性组分为微生物；更优选地，所述微生物为益生菌， 所述益生菌包括食品、保健品和药品中允许使用的双歧杆菌、乳杆菌或革兰氏阳性球菌中的一种或多种；优选地，所述双歧杆菌是乳双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌、长双歧杆菌、短双歧杆菌和青春双歧杆菌中的一种或多种；所述乳杆菌是嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种(保加利亚乳杆菌)、德氏乳杆菌亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌中的一种或多种；所述革兰氏阳性球菌是粪链球菌和乳球菌中的一种或多种。
进一步优选地，所述结肠靶向组合物中益生菌的量为0.01亿-1200亿cfu/g。
优选地，所述辅料包括有利于生物学活性组分生存稳定性的营养物质，该营养物质可以为益生元(如低聚果糖、低聚半乳糖、低聚木糖、低聚乳果糖、大豆低聚糖、果胶、菊粉和蔓越莓粉等)、维生素和/或糖醇。
优选地，所述辅料还包括果胶、海藻酸钠、壳聚糖等对生物学活性组分的结肠靶向递送有益的药用辅料或食品添加剂。
优选地，所述辅料还包括其他粘合剂(阿拉伯胶、瓜尔胶、藻酸、羟甲基纤维素、糊精、卡波姆、麦芽糖、明胶、葡萄糖、乙基纤维素、甲基纤维素、聚环氧乙烷或聚维酮)、填充剂(淀粉、可压性淀粉、变性淀粉、山梨醇、甘露醇、微晶纤维素、糖粉、糊精、无机盐、无水乳糖、乳酸钙)、润滑剂(硬脂酸镁、硬脂酸、矿物油、聚乙二醇、滑石粉、二氧化硅)、崩解剂(羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲纤维素钠、交联聚维酮、干淀粉)等可优化制剂本身性质的其它辅料。
第二方面，本发明提供了一种生物学活性组分结肠靶向制剂，它包含本发明的生物学活性组分结肠靶向组合物。
优选地，所述制剂的剂型为片剂；更优选地，为便于吞服，所述片剂单片质量≤500mg，直径≤10mm。这种剂型可以进一步帮助生物学活性组分在具有大量菌群的结肠中释放，而在胃、小肠和回肠仅部分或少量释放。
第三方面，提供了本发明的生物学活性组分结肠靶向组合物在制备生物学活性组分结肠靶向制剂中的应用。
第四方面，提供了本发明的生物学活性组分结肠靶向制剂的制备方法，包括：
(1)在操作温度<28℃、湿度<40％下，将羟丙甲纤维素、生物学活性组分和辅料混合；
(2)将混合物直接干压成片剂，或干法制粒后压成片剂。
本发明首次将羟丙甲纤维素与生物学活性组分结合，利用羟丙甲纤维素缓 释特性和粘合作用即可经粉末直接干压或干法制粒后压片，从而制得生物学活性组分结肠靶向片剂，避免了湿法制粒和现有结肠靶向相关文献中常见的包衣方法所用的溶剂及温度对生物学活性组分活性的不利影响，且制备工艺简单，易于产业化。所制备的生物学活性组分结肠靶向片剂与市售生物学活性组分片剂相比，由于羟丙甲纤维素的多重作用，可使生物学活性组分经过胃和小肠、到达结肠部位后才释放，耐受胃和小肠环境而不被代谢分解，减小其对小肠可能产生的危害因素，提高生物学活性组分的生物利用度，从而更好地发挥体内活性。特别地就益生菌制剂而言，还可大大减少其他辅料的使用，从而显著提高每片片剂的载菌量，使得日服用量由市售常见的9片以上降至1-2片，并且片形可以更小，更便于吞服。
与现有技术相比，本发明的组合物具有显著改进的结肠靶向效果；此外，可采用食品级辅料，具有极高的安全性；能够便于工业化生产，工艺简单。因此，本发明对于食品、保健品和药品行业均具有重大的开发意义。
附图说明
图1：实施例1-7的片剂在依次经过人工胃液2h、人工肠液3h、人工结肠液18h后的溶出曲线图。
图2：不同粘度的羟丙甲纤维素制备的片剂在依次经过人工胃液2h、人工肠液3h、人工结肠液18h后的溶出曲线图。
具体实施方式
以下通过具体实施例对本发明技术方案及其效果做进一步说明。应当理解，本发明实施例仅用于示例说明本发明的具体实施方法，并不用于限制本发明的保护范围。应用本发明的构思对本发明进行的简单改进都在本发明要求保护的范围内。
如无特别说明，以下实施例中使用的试剂和仪器均是常规试剂和仪器，可以从普通商购途径获得；所使用的操作方法是本领域的常规方法，本领域技术人员结合自己的认知水平和实验能力，能够实现本文所述的实验过程并获得相应的结果。
本发明中所用的益生菌菌粉包括：乳双歧杆菌BLa80、长双歧杆菌BL21、嗜酸乳杆菌LA85和两歧双歧杆菌BBi32，它们来源于江苏紫石微康生物科技有限公司；鼠李糖乳杆菌R11、长双歧杆菌R175和乳双歧杆菌lafti B84，它们来源于法国LALLEMAND公司。所用的羟丙甲纤维素K4M、K15M、K100M 来源于安徽山河辅料有限公司，所用羟丙甲纤维素K100LV和K200M来源于美国陶氏化学。
实施例1
处方：羟丙甲纤维素(HPMC K15M，粘度15000mPa.s)85wt％，乳双歧杆菌BLa80菌粉(活菌数1.0*1011cfu/g)15wt％。
制备方法：
(1)将各物料按处方量混合均匀、过100目筛子，再使之均匀混合；
(2)将粉末混合物用GL2-25型干法制粒机(张家港开创机械制造公司)进行制粒后，压片，单片重150mg，片直径8mm，所含乳双歧杆菌活菌数为1.5*1010cfu/g。
实施例2
处方：羟丙甲纤维素(HPMC K200M，粘度200000mPa.s)65wt％，鼠李糖乳杆菌R11菌粉(活菌数1.5*1011cfu/g)30wt％，硬脂酸镁5wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)将该混合物粉末直接干压成片剂，片重450mg，片直径10mm，所含鼠李糖乳杆菌活菌数为4.5*1010cfu/g。
实施例3
处方：羟丙甲纤维素(HPMC K100M，粘度100000mPa.s)65wt％，嗜酸乳杆菌LA85菌粉(活菌数1.0*1011cfu/g)30wt％，硬脂酸镁5wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)将该混合物粉末直接干压成片剂，片重300mg，片直径10mm，所含嗜酸乳杆菌活菌数为3.0*1010cfu/g。
实施例4
处方：羟丙甲纤维素(HPMC K200M，粘度200000mPa.s)45wt％，乳双歧杆菌BLa80菌粉(活菌数1.0*1011cfu/g)25wt％，长双歧杆菌BL21菌粉(活菌数1.5*1011cfu/g)25wt％，硬脂酸镁5wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)将该混合物粉末直接干压成片剂，片重300mg，片直径10mm，所含乳双歧杆菌活菌数为2.5*1010cfu/g，长双歧杆菌活菌数为3.75*1010cfu/g。
实施例5
处方：羟丙甲纤维素(HPMC K4M，粘度4000mPa.s)70wt％，无水乳糖20wt％，麦芽糖醇5wt％，两歧双歧杆菌BBi32菌粉(活菌数1.5*1011cfu/g)3wt％，二氧化硅1wt％，硬脂酸镁1wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)将该混合物粉末直接干压成片剂，片重300mg，片直径10mm，所含两歧杆菌活菌数为4.5*109cfu/g。
实施例6
处方：羟丙甲纤维素(HPMC K100M，粘度100000mPa.s)13wt％，长双歧杆菌R175菌粉(活菌数5*1010cfu/g)30wt％，异麦芽酮糖醇25wt％，菊粉15wt％，乳酸钙10wt％，果胶5wt％，硬脂酸镁2wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)将该混合物粉末直接干压成片剂，片重300mg，片直径10mm，所含长双歧杆菌活菌数为1.5*1010cfu/g。
实施例7
处方：羟丙甲纤维素(HPMC K100M，粘度100000mPa.s)45wt％，低聚果糖20wt％，嗜乳酸杆菌R418菌粉(活菌数1.5*1011cfu/g)15wt％，乳双歧杆菌lafti B84菌粉(活菌数1*1011cfu/g)10wt％，蔓越莓粉5wt％，山梨糖醇5wt％。
制备方法：
(1)将各物料按处方量混合均匀；
(2)混合物粉末用干法制粒机制粒后，压片，片重450mg，片直径10mm，所含嗜乳酸杆菌活菌数为2.25*1010cfu/g,所含乳双歧杆菌活菌数为1.0*1010cfu/g。
实验例一：本发明实施例的溶出试验
由于益生菌对温度和水均敏感，溶出试验需要取不同时间点的溶出液，因 此以考察结肠释药性的模型药物5-氨基水杨酸代替益生菌进行试验。按照中国药典(2015年版四部0931溶出度与释放度测定法第一法转篮法，50r/min，37℃，将利用上述实施例中的方法和处方制备的片剂(以5-氨基水杨酸代替相应量的益生菌)放入转篮中，依次进行人工胃液(pH1.2)2h、人工肠液(pH6.8)3h、人工结肠液(pH7.8)18h后的溶出测定。各实施例中片剂的溶出结果见图1，结肠释放百分率见表1。
表1：实施例中片剂结肠释放百分率(％)
实施例 1 2 3 4 5 6 7
片剂的结肠释放百分率(％) 61 81 76 55 45 58 74
由图1和表1结果可知：实施例1-7的片剂的结肠释放百分率均可达45％以上，具有显著的结肠靶向效果。
实验例二：不同粘度羟丙甲纤维素片剂的溶出试验
以五种不同粘度的羟丙甲纤维素：HPMC K100LV(粘度:100mPa.s)、K4M、K15M、K100M和K200M，用量均为90wt％，和用量为10wt％的5-氨基水杨酸按本文所述的方法制备片剂和检测溶出结果，结果见图2。图中溶出结果显示：低粘度HPMC(K100LV)制备的片剂经人工胃液和人工肠液后释放即近100％，无法达到结肠释放；而较高粘度HPMC(K4M、K15M、K100M和K200M)制备的片剂在相同条件下可至少保持60％以上在结肠释放，且在人工结肠液中近线性释放，具有显著的结肠靶向效果。
实验例三：活菌数检测实验
以市售思连康片剂(双歧杆菌四联活菌片，500mg/片，其中婴儿双歧杆菌、嗜酸乳杆菌和粪肠球菌分别不低于0.5*106cfu/g，蜡样芽孢杆菌不低于0.5*105cfu/g，辅料为淀粉和奶粉类物质)与上述实施例制得的片剂溶出后进行活菌数检测。
(一)实验方法
(1)培养基配制
取MRS琼脂粉39.7g，加入600ml蒸馏水中，加热溶解。2.9mm玻璃培养皿用自来水洗净后，再用蒸馏水冲洗三遍，晾干。
(2)灭菌
培养基和培养皿置于灭菌锅中，121℃，103.4kPa灭菌30min。
(3)培养基置于52℃水浴锅中备用，培养皿室温放置冷却备用。
(4)溶出条件
按照中国药典(2015年版四部0931溶出度与释放度测定法第一法转篮法，50r/min，37℃)，将市售思连康片剂进行人工胃液(pH1.2)2h后取出，将实施例1-7的片剂放入转篮中，依次进行人工胃液(pH1.2)2h、人工肠液(pH6.8)3h后取出。
(二)培养
取上述未经与经过溶出处理的思连康片剂与实施例1-7的片剂样品，分别置于玻璃研钵中研碎，然后用50ml生理盐水稀释，混匀后取1ml混合液10倍倍比稀释，稀释后取各个稀释度0.1ml涂布于MRS培养基上。将涂布后的平板至于厌氧袋中放在37℃恒温培养箱中培养48h后将平板取出进行菌落计数。
(三)结果
市售思连康片剂经人工胃液(pH 1.2、37℃)2h处理后，在10-4倍稀释仍无菌落数；而实施例1-7的片剂经人工胃液(pH 1.2、37℃)2h、人工肠液(pH 6.8、37℃)3h处理后，活菌数仍较多，与市售思连康片剂相比有显著性差异，具体活菌数检测结果见表2。该比较结果说明，本发明的益生菌片剂使得益生菌可以成功地耐受胃和小肠环境，从而保持其一定的活菌数递送到结肠部位释放，并且本发明对不同厂家来源的不同菌种均可保护其被递送到结肠部位释放。
表2：市售思连康和实施例1-7片剂溶出后活菌数检测结果
Figure PCTCN2017110074-appb-000001

Claims (10)

  1. 一种生物学活性组分结肠靶向组合物，包括：羟丙甲纤维素、生物学活性组分和辅料，其中，所述羟丙甲纤维素的重量百分含量为10～99％，所述生物学活性组分的重量百分含量为1～60％，辅料的重量百分含量为0～80％；其中，所述羟丙甲纤维素的粘度>1000mPa.s。
  2. 根据权利要求1所述的组合物，其中，所述羟丙甲纤维素的重量百分含量为40～90％，所述生物学活性组分的重量百分含量为10～40％，所述辅料的重量百分含量为0～50％。
  3. 根据权利要求1或2所述的组合物，其中，所述羟丙甲纤维素的粘度为15000mPa.s～200000mPa.s。
  4. 根据权利要求3所述的组合物，其中，所述生物学活性组分为微生物，优选为益生菌，更优选地，所述益生菌包括双歧杆菌、乳杆菌或革兰氏阳性球菌中的一种或多种；进一步优选地，所述双歧杆菌是乳双歧杆菌、婴儿双歧杆菌、两歧双歧杆菌、长双歧杆菌、短双歧杆菌和青春双歧杆菌中的一种或多种；所述乳杆菌是嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种、德氏乳杆菌亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌中的一种或多种；所述革兰氏阳性球菌是粪链球菌和乳球菌中的一种或多种。
  5. 根据权利要求4所述的组合物，其中，所述组合物中益生菌的量优选为0.01亿-1200亿cfu/g。
  6. 根据权利要求5所述的组合物，其中，所述辅料包括有利于生物学活性组分生存稳定性的营养物质、对生物学活性组分的结肠靶向递送有益的药用辅料或食品添加剂、和/或优化制剂本身性质的其它辅料。
  7. 一种生物学活性组分结肠靶向制剂，包含权利要求1-6任一项所述的组合物。
  8. 根据权利要求7所述的生物学活性组分结肠靶向制剂，其中，所述制剂的剂型为片剂；优选地，所述片剂的单片质量≤500mg，直径≤10mm。
  9. 权利要求1-6任一项的组合物在制备生物学活性组分结肠靶向制剂中的应用。
  10. 一种制备权利要求8所述的生物学活性组分结肠靶向制剂的方法，包括：
    (1)在操作温度为<28℃、湿度<40％下，将羟丙甲纤维素、生物学活性组分和辅料混合；
    (2)将混合物直接干压成片剂，或干法制粒后压成片剂。
PCT/CN2017/110074 2016-11-11 2017-11-09 一种生物学活性组分结肠靶向组合物及其应用 Ceased WO2018086550A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/349,093 US11337926B2 (en) 2016-11-11 2017-11-09 Colon-targeted composition of biological active component and application thereof
RU2019116519A RU2744452C2 (ru) 2016-11-11 2017-11-09 Композиция для направленной доставки биологически активного компонента в толстую кишку и ее применение
EP17869993.0A EP3539538B1 (en) 2016-11-11 2017-11-09 Biological active component colon-targeted composition and application thereof
JP2019546961A JP6989154B2 (ja) 2016-11-11 2017-11-09 生物学的活性成分の結腸標的組成物、およびその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611013848.3A CN108066296B (zh) 2016-11-11 2016-11-11 一种生物学活性组分结肠靶向组合物及其应用
CN201611013848.3 2016-11-11

Publications (1)

Publication Number Publication Date
WO2018086550A1 true WO2018086550A1 (zh) 2018-05-17

Family

ID=62109436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/110074 Ceased WO2018086550A1 (zh) 2016-11-11 2017-11-09 一种生物学活性组分结肠靶向组合物及其应用

Country Status (6)

Country Link
US (1) US11337926B2 (zh)
EP (1) EP3539538B1 (zh)
JP (1) JP6989154B2 (zh)
CN (1) CN108066296B (zh)
RU (1) RU2744452C2 (zh)
WO (1) WO2018086550A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220047515A1 (en) * 2018-12-14 2022-02-17 Dpl Pharma S.P.A. Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
CN115644448A (zh) * 2022-09-07 2023-01-31 西安诺众康健生物科技有限责任公司 一种肠道益生菌包埋保护方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966440B2 (en) * 2019-01-05 2021-04-06 Foremost Technologies and Products, Inc. High pressure processing of foods and food supplements
CN109652349B (zh) * 2019-02-25 2021-03-02 江南大学 一株能够缓解特应性皮炎的长双歧杆菌及其应用
EP4319776A4 (en) * 2021-04-07 2025-02-19 Siolta Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
CN113274369B (zh) * 2021-04-29 2022-10-14 暨南大学 一种结肠靶向的口服益生菌微囊及其制备方法与应用
CN114703102B (zh) * 2022-04-19 2023-05-05 微康益生菌(苏州)股份有限公司 一种缓解便秘的两歧双歧杆菌及其应用
CN118697053B (zh) * 2024-08-27 2024-12-13 潍坊康地恩生物科技有限公司 一种肠道定点缓释的三层包埋结构益生菌晶球及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1853655A (zh) * 2005-04-28 2006-11-01 杨明 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法
CN1921838A (zh) * 2004-02-19 2007-02-28 兰贝克赛实验室有限公司 双丙戊酸钠的缓释药物组合物
CN102106925A (zh) * 2009-12-28 2011-06-29 于莲 枸杞多糖双歧杆菌合生元结肠靶向微生态调节剂
CN105120847A (zh) * 2013-03-14 2015-12-02 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
CN101843337B (zh) * 2010-06-07 2012-10-10 陕西科技大学 一种益生菌片的制备方法
JP5087167B2 (ja) * 2010-12-28 2012-11-28 フロイント産業株式会社 ビフィズス菌大腸デリバリーカプセル及びその製造方法
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
BR112016031000B1 (pt) * 2014-07-01 2022-01-25 Probi USA, Inc. Forma de dosagem em camadas e método para fazer a mesma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921838A (zh) * 2004-02-19 2007-02-28 兰贝克赛实验室有限公司 双丙戊酸钠的缓释药物组合物
CN1853655A (zh) * 2005-04-28 2006-11-01 杨明 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法
CN102106925A (zh) * 2009-12-28 2011-06-29 于莲 枸杞多糖双歧杆菌合生元结肠靶向微生态调节剂
CN105120847A (zh) * 2013-03-14 2015-12-02 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
US20160022592A1 (en) 2013-03-14 2016-01-28 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALBERTINI BVITALI BPASSERINI N ET AL.: "Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis [J", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 40, no. 4, 2010, pages 359 - 366, XP027066416, DOI: doi:10.1016/j.ejps.2010.04.011
CALINESCU CMATEESCU M A: "Carboxymethyl high amylase starch: chitosan self-stabilized matrix for probiotic colon delivery [J", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 70, no. 2, 2008, pages 582 - 589
KLEMMER K JKORBER D RNICHOLAS H ET AL.: "Pea proteinbased capsules for probiotic and prebiotic delivery [J", INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 46, no. 11, 2011, pages 2248 - 2256, XP055187943, DOI: doi:10.1111/j.1365-2621.2011.02743.x
See also references of EP3539538A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220047515A1 (en) * 2018-12-14 2022-02-17 Dpl Pharma S.P.A. Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
CN115644448A (zh) * 2022-09-07 2023-01-31 西安诺众康健生物科技有限责任公司 一种肠道益生菌包埋保护方法

Also Published As

Publication number Publication date
RU2019116519A (ru) 2020-12-11
EP3539538A1 (en) 2019-09-18
EP3539538B1 (en) 2025-07-16
RU2019116519A3 (zh) 2020-12-11
US20190274960A1 (en) 2019-09-12
RU2744452C2 (ru) 2021-03-09
CN108066296B (zh) 2020-11-17
JP6989154B2 (ja) 2022-01-05
US11337926B2 (en) 2022-05-24
CN108066296A (zh) 2018-05-25
EP3539538C0 (en) 2025-07-16
JP2020500927A (ja) 2020-01-16
EP3539538A4 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
CN108066296B (zh) 一种生物学活性组分结肠靶向组合物及其应用
TWI574633B (zh) 包含益生菌及益生質成分及礦物鹽及乳鐵蛋白之組合物
CN101897729B (zh) 一种益生菌组合物及其制剂
CN104740138A (zh) 包含芦荟、益生菌和益生元的组合物及其用途
CN104413334A (zh) 可食用组合物及其制备方法和用途
JP5735548B2 (ja) プロバイオティクス製剤ならびに５−ｈｔ４受容体作動薬を含有する経口投与用複合製剤、及びその製造方法
WO1999064023A1 (en) Lactic acid bacterium-containing compositions, drugs and foods
JP6637725B2 (ja) ウイルス感染症の予防及び／又は治療剤
BR112016031000B1 (pt) Forma de dosagem em camadas e método para fazer a mesma
CN102333534B (zh) 用于治疗胃溃疡和十二指肠溃疡的包括质子泵抑制剂及益生元的药物组合物
CN106974262B (zh) 肠道益生杆菌在治疗和预防肥胖及其相关疾病中的应用
Lokhande et al. A systematic study of probiotics-an update review
JP5415232B2 (ja) 生菌製剤の製造方法
CN121752283A (zh) 用于治疗病症的微生物群组合物和方法
JP5681533B2 (ja) 消化管痛の予防又は軽減剤
JP4603116B2 (ja) 乳酸菌含有組成物、医薬及び食品
CN107073048B (zh) 含有乳酸菌的组合物
JP5940869B2 (ja) 腸内環境改善有核錠製剤及びハードカプセル製剤
JP2005247775A (ja) 予防・治療用栄養組成物
JP6402016B2 (ja) 神経機能改善剤
JP7583498B1 (ja) 製剤組成物
Ullah et al. Prebiotics and Probiotics: Concept and Advances
CN120005775A (zh) 复合益生菌、其制剂、后生元组合物及其在防治幽门螺旋杆菌中的应用和产品
JP2025031495A (ja) 錠剤及びその製造方法
Temple et al. Probiotic Bifidobacterium species: potential beneficial effects in diarrheal disorders 1 2 Debolina Ray3, Gianfranco Alpini1, 2, 3 & Shannon Glaser1, 2, 3 3 From Research, Central Texas Veterans Health Care System, 2 BaylorScott & White 4 Digestive Disease Research Center, BaylorScott & White, 3 Department of Medicine, 5

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869993

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019546961

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017869993

Country of ref document: EP

Effective date: 20190611

WWG Wipo information: grant in national office

Ref document number: 2017869993

Country of ref document: EP